Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 36, 2012, Pages 14476-14481

  Greulich, Heidi ^a,b,c,d   Kaplan, Bethany ^a,d   Mertins, Philipp ^d   Chen, Tzu Hsiu ^d   Tanaka, Kumiko E ^a,d   Yun, Cai Hong ^e   Zhang, Xiaohong ^a   Lee, Se Hoon ^a   Cho, Jeonghee ^a   Ambrogio, Lauren ^d   Liao, Rachel ^a,d   Imielinski, Marcin ^a,d   Banerji, Shantanu ^a,d   Berger, Alice H ^a,d   Lawrence, Michael S ^d   Zhang, Jinghui ^f   Pho, Nam H ^a,d   Walker, Sarah R ^a   Winckler, Wendy ^d   Getz, Gad ^a,b,c   Frank, David ^a   Hahn, William C ^a,b,d   Eck, Michael J ^a   Manid, D R ^d   Jaffe, Jacob D ^d   Carr, Steven A ^d   Wong, Kwok Kin ^a,b,c   Meyerson, Matthew ^a,b,c,d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Bladder cancer; Breast cancer; HER2

Indexed keywords

AFATINIB; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; EPHRIN RECEPTOR A3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 4; INTERLEUKIN 3; K RAS PROTEIN; NERATINIB; NTRK3 PRTOTEIN; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; DIMERIZATION; EXTRACELLULAR MATRIX; GENE MUTATION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ALLELES; ANIMALS; CELL MOVEMENT; CLONING, MOLECULAR; DIMERIZATION; DNA PRIMERS; IMMUNOBLOTTING; LUNG NEOPLASMS; MICE; MUTATION; NIH 3T3 CELLS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RETROVIRIDAE; TANDEM MASS SPECTROMETRY;

EID: 84865994665     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203201109     Document Type: Article

References (47)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236.
2. Sharma SV, Settleman J (2010) Exploiting the balance between life and death: Targeted cancer therapy and "oncogenic shock" Biochem Pharmacol 80:666-673.
3. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297:63-64.
4. Druker BJ, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042. (Pubitemid 32267973)
5. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139. (Pubitemid 38637993)
6. Mok TS, et al. (2009) Ge fitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957.
7. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500. (Pubitemid 38720929)
8. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101:13306-13311. (Pubitemid 39209661)
9. Kwak EL, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703.
10. Geyer CE, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743. (Pubitemid 46021510)
11. Slamon DJ, et al. (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182. (Pubitemid 17231334)
12. Ding L, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
13. Greulich H (2010) The genomics of lung adenocarcinoma: Opportunities for targeted therapies. Genes Cancer 1:1200-1210.
14. Taylor JG, 6th, et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 119:3395-3407.
15. Greulich H, Pollock PM (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17:283-292.
16. Minami Y, et al. (2007) The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26:5023-5027. (Pubitemid 47172642)
17. Wang SE, et al. (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38.
18. Kan Z, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869-873.
19. Banerji S, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405-409.
20. Shah SP, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395-399.
21. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
22. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607.
23. Di Fiore PP, et al. (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182. (Pubitemid 17095921)
24. Shigematsu H, et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646. (Pubitemid 40478587)
25. Shimamura T, et al. (2006) Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66:6487-6491. (Pubitemid 44085601)
26. Stephens P, et al. (2004) Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526.
27. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
28. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
29. Cho HS, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760.
30. Fiorentino L, et al. (2000) Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 20:7735-7750.
31. Aceto N, et al. (2012) Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18:529-537.
32. Shi ZQ, Yu DH, Park M, Marshall M, Feng GS (2000) Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol 20:1526-1536. (Pubitemid 30100172)
33. Sun T, et al. (2011) Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 144:703-718.
34. Li D, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711.
35. Dutt A, et al. (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105:8713-8717. (Pubitemid 351987745)
36. Wai DH, et al. (2000) The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene 19:906-915. (Pubitemid 30153748)
37. Lee W, et al. (2010) The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465:473-477.
38. Chen CL, et al. (2010) Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res 20:447-457.
39. Stamatoyannopoulos JA, et al. (2009) Human mutation rate associated with DNA replication timing. Nat Genet 41:393-395.
40. Chesi M, et al. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97:729-736. (Pubitemid 32113407)
41. d'Avis PY, et al. (1998) Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ 9:71-78.
42. Padhy LC, Shih C, Cowing D, Finkelstein R, Weinberg RA (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28:865-871.
43. Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657. (Pubitemid 16063129)
44. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI (1989) A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230-231. (Pubitemid 19126396)
45. Siegel PM, Dankort DL, Hardy WR, Muller WJ (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068-7077. (Pubitemid 24326370)
46. Siegel PM, Muller WJ (1996) Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc Natl Acad Sci USA 93:8878-8883. (Pubitemid 26281985)
47. Ong SE, Mann M (2006) A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 1:2650-2660.